Ameriprise
KDNY

Ameriprise’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ameriprise’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,632
Closed -$56K – 3841
2020
Q3 		$56K Hold
4,632
– – ﹤0.01% 3671
2020
Q2 		$54K Hold
4,632
– – ﹤0.01% 3615
2020
Q1 		$63K Buy
+4,632
New +$54.8K ﹤0.01% 3566
2016
Q3 		– Sell
-6,099
Closed -$345K – 3852
2016
Q2 		$345K Buy
6,099
+1,245
+26% +$75.6K ﹤0.01% 3326
2016
Q1 		$311K Buy
4,854
+606
+14% +$49K ﹤0.01% 3344
2015
Q4 		$598K Buy
4,248
+677
+19% +$91.9K ﹤0.01% 3178
2015
Q3 		$346K Buy
3,571
+739
+26% +$88K ﹤0.01% 3425
2015
Q2 		$430K Buy
+2,832
New +$468K ﹤0.01% 3508

Other funds holding KDNY

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's KDNY Position: Q4 2020 in Review

Ameriprise sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2020, closing a stake of 4,632 shares — an estimated $56K sold.

Ameriprise first reported a position in KDNY in Q2 2015 and held it in 8 quarters. The position peaked at $598K in Q4 2015. 77 funds tracked by Wall St. Rank hold KDNY as of Q4 2020.

  • Ameriprise reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Ameriprise sold 4,632 Chinook Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $56K.
  • Ameriprise first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 8 quarters.
  • Ameriprise's Chinook Therapeutics, Inc. Common Stock position peaked at $598K in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.